Showing posts with label Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C. Show all posts
Showing posts with label Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C. Show all posts
Monday, May 2, 2016

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

›
In continuation of my update on  daclatasvir Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvi...